Man-made chemicals which mimic oestrogen contribute to breast cancer

Health campaigners are urging politicians to act on the growing body of scientific evidence that links exposure to certain chemicals to spiralling rates of breast cancer. Scientists have known for decades that a woman's risk of developing breast cancer is influenced both by the levels of oestrogen produced by her own body and her use of drugs containing man-made oestrogens, such as hormone replacement therapy (HRT).

Now a new report, "Breast cancer and exposure to hormonally active chemicals", highlights the role of manmade chemicals which act like hormones in the development of breast cancer. The report, which was commissioned by the Health and Environment Alliance (HEAL) and CHEM Trust, was presented to Members of the European Parliament in Brussels on 2 April.

"Good laboratory and epidemiological evidence exists suggesting that man-made chemicals which mimic oestrogen contribute to breast cancer," stated the report's author, Professor Andreas Kortenkamp of the University of London's School of Pharmacy. "We will not be able to reduce the risk of breast cancer without addressing preventable causes, particularly exposure to chemicals."

Cases of breast cancer are on the rise across Europe, and over a million cases are diagnosed worldwide every year. "Although late age at first child birth and genetics are shown to contribute to the increase in breast cancer, the sheer number of newly diagnosed cases cannot solely be explained by these factors," the report reads. "Evidence is emerging that environmental influences, including chemical exposure, also play a role."

At the launch of the report, Professor Kortenkamp presented evidence showing that while low levels of individual chemicals have no discernible impact on breast cancer, when mixtures of chemicals are considered together, they have a clear impact, even when the level of each individual chemical is very low.

Professor Kortenkamp also highlighted the importance of exposure levels at different times in a woman's life; women are particularly vulnerable to elevated oestrogen levels in the womb, when the breast tissue is laid down, and at puberty, when the breasts' ductal system grows.

For example, research shows that women who were exposed to the pesticide DDT during puberty are more likely to develop breast cancer than women who were exposed to it later in life, when their breast tissue was less vulnerable.

Meanwhile another study focussed on women whose mothers took the drug DES (diethylstilboestrol) to avoid miscarriages, and so were exposed to synthetic oestrogens in the womb. The results revealed that these women face a doubled risk of developing breast cancer.

The list of chemicals which act like hormones, and the products containing them, is long. Some of these chemicals, including DDT and some other pesticides, are already banned. However, there are many more, including bisphenol A (BPA), which is found in plastic food storage containers; parabens, which are used in cosmetics; UV-filters from sunscreens and alkylphenols, which are found in plastics, paints, inks and detergents.

Scientists and health campaigners argue that as these chemicals are found in such a wide range of products, it is impossible for women to avoid exposure to them. The time is therefore ripe for regulators to take action to remove these chemicals from the environment, they say.

As Professor Kortenkamp pointed out, the European Union has funded a lot of excellent research on this subject. However, "this is not entirely matched by an equally well founded and well thought out regulatory approach to complement this, to act on the basis of scientific evidence," he told CORDIS News.

Meanwhile more research is needed. "We need to do more epidemiological studies to find out why women get breast cancer - how do they differ from the ones who don't get breast cancer," said Dr Annie Sasco, Team Leader for Epidemiology for Cancer Prevention at the French National Institute for Health and Medical Research (INSERM).

Doing these studies will require the use of biological markers to determine which products people have been exposed to. Toxicological studies and experimental studies in animals are also needed, Dr Sasco added.

"The efforts to screen for oestrogen-like chemicals need to be redoubled," said Professor Kortenkamp. "We are far from having a complete picture about this."

For more information, please visit:
http://www.chemicalshealthmonitor.org/

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...

GSK and Vir Biotechnology announce United States g…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase so...

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer and BioNTech receive expanded U.S. FDA emer…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...